Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910679 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Naoya Koizumi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo 194-8543, Japan. Hauptthemen laut MEDLINE: Genetic Therapy, Capsid Proteins. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Numerous gene therapy drugs for cancer have received global approval, yet their efficacy against solid tumors remains inadequate. Our previous research indicated that the fiber protein, a component of the adenovirus capsid, can propagate from infected cells to neighboring cells that express the adenovirus receptor. We hypothesize that merging this fiber protein with an anti-cancer protein could enable the anti-cancer protein to disseminate around the transfected cells, presenting a novel approach to cancer gene therapy. In our study, we discovered that the knob region of the adenovirus type 5 fiber protein is the smallest unit capable of spreading to adjacent cells in a receptor-specific manner. We also showed that the recombinant knob protein infiltrates cells after dispersing to surrounding cells. To assess the potential of the knob protein to augment gene therapy for solid tumors in mice, we expressed a fusion gene of the A subunit of cytotoxic cholera toxin and the knob region in mouse tumors. We found that this fusion protein only inhibited tumor growth in receptor-expressing mouse melanomas, and this inhibitory effect persisted even in mice with anti-knob antibodies. Our study’s findings propose a novel cancer gene therapy strategy that enhances therapeutic effects by specifically delivering therapeutic proteins, expressed from in vivo administered genes, to target molecules. This outcome offers a fresh perspective on gene therapy for solid cancers, and we anticipate that knob proteins will serve as a platform for this method.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pharmaceutics and Biopharmaceutics, Showa Pharmaceutical University, Tokyo 194-8543, Japan.
- Division of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kawasaki 210-9501, Japan.
Förderung
- JSPS KAKENHI
Zitieren
APA
Koizumi, N., Hirai, T., Kano, J., Sato, A., Suzuki, Y., Sasaki, A., Nomura, T., & Utoguchi, N. (2024). Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910679
Vancouver
Koizumi N, Hirai T, Kano J, Sato A, Suzuki Y, Sasaki A, et al. Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910679
BibTeX
@article{Koizumi2024,
author = {Koizumi, Naoya and Hirai, Takamasa and Kano, Junpei and Sato, Anna and Suzuki, Yurika and Sasaki, Arisa and Nomura, Tetsuya and Utoguchi, Naoki},
title = {Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910679}
}
EUVIMED